Lisata Therapeutics, Inc. (LSTA)
Lisata Therapeutics receives 2025 BioTech Breakthrough Award for 'Overall BioPharma Solution of the Year'
Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has won the “Overall BioPharma Solution of the Year” in the fifth annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, an independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services throughout the world. The clinical-stage pharmaceutical company said the award is in recognition of its unique therapeutic approach and focused clinical development plans, designed to produce products to address the unmet medical needs of patients with advanced solid tumors.
Lisata Therapeutics reports preclinical data showing certepetide's potential to enhance cancer drug delivery
Lisata Therapeutics Inc (NASDAQ:LSTA) has reported promising preclinical results suggesting its iRGD cyclic peptide, certepetide, could enhance the effectiveness of antibody-drug conjugates (ADCs) in cancer treatment. The data, presented by Lisata's licensing partner Catalent at the 16th Annual World ADC San Diego Conference, showed that certepetide may improve tumor penetration and broaden the distribution of cytotoxic agents within tumors.
Lisata Therapeutics, Inc. (LSTA) Q2 2025 Earnings Call Transcript
Lisata Therapeutics, Inc. (NASDAQ:LSTA ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants David J. Mazzo - President, CEO & Director James Nisco - Senior VP of Finance, Treasurer, CAO & Principal Financial and Accounting Officer Kristen K.
Lisata Therapeutics advances lead cancer drug, expects key trial results by year-end
Lisata Therapeutics Inc (NASDAQ:LSTA) said on Thursday it is making steady progress in advancing its pipeline of oncology drug candidates, with several key clinical trial readouts anticipated through the remainder of 2025 and into 2026. The company reaffirmed its financial runway into the fourth quarter of next year, positioning it to continue developing certepetide, its lead investigational therapy for advanced solid tumors.
Lisata Therapeutics and WARPNINE complete enrollment in iLSTA trial, share encouraging preliminary results
Lisata Therapeutics Inc (NASDAQ:LSTA) and WARPNINE announced the completion of patient enrollment in the Phase 1b/2a iLSTA trial, which is evaluating Lisata's therapy candidate certepetide in combination with standard-of-care chemotherapy and immunotherapy in pancreatic cancer. It is evaluating the therapy in patients with locally advanced non-resectable pancreatic ductal adenocarcinoma (PDAC), rather than metastatic PDAC.
Lisata Therapeutics expands IP with key patent covering certepetide's chemical structure and uses
Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has been issued a new US composition of matter patent for its investigational drug candidate certepetide. The United States Patent and Trademark Office (USPTO) has granted the company US Patent No 12,351,653, which provides protection for certepetide through March 2040, with the possibility of a patent term extension.
Lisata Therapeutics and GATC advance AI-driven opioid use disorder therapy - ICYMI
Lisata Therapeutics Inc (NASDAQ:LSTA) CEO Dr David Mazzo talked with Proactive about the company's deepening collaboration with GATC Health. Mazzo explained that the partnership has evolved due to the complementary strengths of both organisations—Lisata's clinical and regulatory expertise and GATC's AI-powered drug discovery platform, MAT.
Lisata Therapeutics reports encouraging data from ASCEND Cohort B evaluating certepetide in pancreatic cancer
Lisata Therapeutics Inc (NASDAQ:LSTA), in collaboration with the Australasian Gastro-Intestinal Trials Group and the NHMRC Clinical Trials Centre at the University of Sydney, announced positive preliminary results from Cohort B of the ASCEND Phase 2b clinical trial evaluating certepetide in combination with standard-of-care chemotherapy in metastatic pancreatic ductal adenocarcinoma (mPDAC). The ASCEND trial is a 158-patient, double-blind, randomized, placebo-controlled study assessing the addition of certepetide to standard-of-care gemcitabine and nab-paclitaxel.
Lisata Therapeutics to lead development of OUD therapy under expanded alliance with GATC Health
Lisata Therapeutics Inc (NASDAQ:LSTA) and GATC Health have expanded their strategic alliance aimed at accelerating and improving the success rate of drug development using artificial intelligence (AI). The expanded collaboration builds on prior work in which GATC provided AI-based analysis supporting Lisata's certepetide drug candidate.
Lisata Therapeutics, Inc. (LSTA) Q1 2025 Earnings Conference Call Transcript
Lisata Therapeutics, Inc. (NASDAQ:LSTA ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants John Menditto - VP of IR and Corporate Communications David Mazzo - President and CEO James Nisco - SVP of Finance and Treasury and Chief Accounting Officer Kristen Buck - EVP of R&D and Chief Medical Officer Conference Call Participants Kemp Dolliver - Brookline Capital Market Pete Enderlin - MAZ Partners Operator Welcome to the Lisata Therapeutics First Quarter 2025 Financial Results and Business Update Conference Call. Currently, all participants are in listen-only mode.
Lisata eyes key trial milestones in 2025 as certepetide development gains momentum
Lisata Therapeutics Inc (NASDAQ:LSTA) said on Thursday it expects a data-rich year ahead as it advances multiple trials of its lead asset, certepetide, a novel peptide-based therapy being tested in a range of solid tumors. The New Jersey-based company said it remains focused on progressing certepetide through clinical and preclinical studies, with several important data readouts expected over the course of 2025 and into 2026, including results from the second cohort of its ASCEND trial in metastatic pancreatic cancer and preclinical work with Catalent's antibody-drug conjugate (ADC) platform.
Lisata Therapeutics CEO discusses AI drug discovery collaboration - ICYMI
Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo joined Proactive to discuss the company's strategic collaboration with GATC Health, a leader in artificial intelligence-driven drug discovery. Mazzo explained that GATC's technology will be used to analyze Lisata's lead candidate certepetide and identify potential new drug combinations.
